; and (6) encourages the President of the United States to form a Sickle Cell Disease Interagency Cabinet, which would be convened by the White House, bringing together departments and Federal agencies across Government to address sickle cell disease on multiple fronts, which would include, but are not limited to, the Department of Health and Human Services, Department of Veterans Affairs, National Institutes of Health, Food and Drug Administration, and Centers for Medicare & Medicaid Services to begin working toward policies that will support equitable and appropriate access to innovative SCD therapies, and in this regard, the House of Representatives urges that the options to be considered not only address access to potential future curative treatments, but also address the bias that this population continues to face within both the United States and global health care systems.